Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy

doi:10.21037/atm-22-1165

	Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy
	Xu, Liwei 1; Qi, Yajun 2; Jiang, Youhua 1; Ji, Yongling 3; Zhao, Qiang 1; Wu, Jie 1; Lu, Weishan 1; Wang, Yinjie 1; Chen, Qixun 1; Wang, Changchun 1
刊名	ANNALS OF TRANSLATIONAL MEDICINE
	2022-03-18
关键词	Gut microbiome esophageal squamous cell carcinoma (ESCC) neoadjuvant therapy immunotherapy
ISSN号	2305-5839
DOI	10.21037/atm-22-1165
通讯作者	Chen, Qixun(chenqixun64@163.com) ; Wang, Changchun(sbl0363@dingtalk.com)
英文摘要	Background: The gut microbiome is associated with the response to immunotherapy in a variety of advanced cancers. However, the influence of the gut microbiome on locally advanced esophageal squamous cell carcinoma (ESCC) during programmed cell death protein 1 (PD-1) antibody immunotherapy plus chemotherapy is not clearly demonstrated. To explore the crosstalk between the gut microbiome and clinical response in locally advanced thoracic ESCC during neoadjuvant camrelizumab and chemotherapy Methods: Patients who were diagnosed with locally advanced thoracic ESCC and had not received treatment were enrolled. The treatment regimen was two cycles of camrelizumab combined with carboplatin and albumin paclitaxel before surgery. The research endpoints were pathological complete response (pCR) and major pathological response (MPR). Fecal samples were collected at three time points: before neoadjuvant therapy, after two cycles of neoadjuvant therapy, and after surgery. We performed 16S ribosomal ribonucleic acid (rRNA) V3-V4 sequencing of the gene amplicons of fecal samples, as well as bacterial diversity and differential abundance analyses. Results: A total of 46 patients were recruited, and 44, 42, and 35 fecal samples were collected at the three time points, respectively. Statistically significant differences were observed in the amplicon sequence variant (ASV)-level alpha diversity indices, including Chaol, Shannon, and Good's coverage, between the three time points. The non-pCR-enriched gut microbiota included Proteobacteria, Dialister, Aeromonadalcs, Pseudomonadales, Thermi, Deinococci, Moraxellaceae, Rhodocyclales, Rhodocyclaceae, and Acinetobactcr. he non-MPR-enriched gut microbiota included Pseudomonadales and the mitochondria family. The MPR-enriched gut microbiota included the Barnesiellaceae, Pyramidobacter, Dethiosulfovibrionaceae, Odoribacteraceae, Butyricimonas, Prevotella, Barnesiella, and Odoribacter. Patients with >= 3 grade adverse events (AEs) exhibited enrichment in the Succiniclasticum, Nakamurella, Rhizobium, Granulicella, Phyllobacteriaceae, Pelagibacteraceae, Actinosynnemataceae, Aquirestis, Flavisolibacter, Chelativorans, Coxiellaceae Acidicapsa, Acidobacteriaceae, Lentzea, Staphylococcus, Plesiomonas, Dysgonomonas, Pseudonocardia, and Ellin6075. Conclusions: We found that the diversity of the gut microbiome declined after neoadjuvant PD- I antibody immunotherapy plus chemotherapy and surgery. Patients with pCR had different types and proportions of gut microbiota before treatment compared to those without pCR. We also observed the difference between patients with or without >= grade 3 AEs. The taxonomic features of the gut microbiome are potential biomarkers that could predict the pathological response and AEs.
资助项目	Medical and Health Technology Plan of Zhejiang Province[2019KY330] ; Medical and Health Technology Plan of Zhejiang Province[2020KY057] ; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province[2022E10021]
WOS关键词	PLUS CHEMOTHERAPY
WOS研究方向	Oncology ; Research & Experimental Medicine
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000777131800001
资助机构	Medical and Health Technology Plan of Zhejiang Province ; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128241]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Qixun; Wang, Changchun
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg,Key Lab Prevent Diag & Therapy U, Hangzhou 310022, Peoples R China 2.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Pharm, Hangzhou, Peoples R China 3.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp,Dept Thorac, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Xu, Liwei,Qi, Yajun,Jiang, Youhua,et al. Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy[J]. ANNALS OF TRANSLATIONAL MEDICINE,2022.
APA	Xu, Liwei.,Qi, Yajun.,Jiang, Youhua.,Ji, Yongling.,Zhao, Qiang.,...&Wang, Changchun.(2022).Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.ANNALS OF TRANSLATIONAL MEDICINE.
MLA	Xu, Liwei,et al."Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy".ANNALS OF TRANSLATIONAL MEDICINE (2022).